A new predictive factor VGF based on IHC experiments, gene pathways and molecular functional groups for tumor immune microenvironment and prognosis of adrenocortical carcinoma
VGF could serve as a valuable marker for patient stratification, monitoring disease progression, and predicting responses to immunotherapies. Future studies should focus on investigating circulating VGF levels as a non-invasive biomarker for ACC to improve clinical management and treatment outcomes.
Authors
- Keyuan Lou
- Jitao Wu (ORCID: https://orcid.org/0000-0003-3178-9334)
- Junpeng Chi (ORCID: https://orcid.org/0009-0000-8418-5134)
- Jiankun Zhang (ORCID: https://orcid.org/0000-0002-9147-2569)
- Yuanshan Cui
Institutions
- Qingdao University (CN)
- Weifang Medical University (CN)
- Yuhuangding Hospital (CN)
- Weifang People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-17
- DOI
- https://doi.org/10.3389/fimmu.2025.1542780
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00